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http:WHAT THIS PAPER ADDS
The RELACS trial is one of the most powerful randomized studies providing 5 year follow up data for the
comparison of endovenous laser ablation and conventional surgery of great saphenous vein incompetence. Both
treatments are deemed to be equivalent concerning safety and mid-term efﬁcacy. However, the present results
suggest long-term superiority of conventional surgery in terms of same site clinical and saphenofemoral duplex
recurrence, which underlines the need for more evidence in the ﬁeld of endovenous treatment approaches.Objective: To compare the long-term clinical efﬁcacy of endovenous laser ablation (EVLA) with high ligation and
stripping (HLS) as standard treatment for great saphenous vein (GSV) incompetence.
Design: Investigator initiated two centre randomized controlled trial with 5 year follow up.
Materials and methods: Interventions were performed on ambulatory and hospitalized patients at two vein
centres, a university dermatology department (EVLA) and a specialized vein clinic (HLS). Four hundred patients
suffering from GSV incompetence were assigned to EVLA or HLS of the GSV. One hundred and eighty ﬁve and 161
patients (¼limbs), respectively, were treated per protocol. Main outcome measures were clinically recurrent
varicose veins after surgery (REVAS classiﬁcation, primary study objective), Duplex detected saphenofemoral
recurrence, clinical venous severity scoring (Homburg Varicose Vein Severity Score), quality of life (Chronic
Venous Insufﬁciency Questionnaire 2), side effects, and patient satisfaction 5 years after treatment.
Results: Two hundred and eighty one legs (81% of the study population) were evaluated with a median follow up
of 60.4 (EVLA) and 60.7 months (HLS). Overall, REVAS was similarly observed in both groups: 45% (EVLA) and 54%
(HLS), p ¼ .152. Patients of the EVLA group showed signiﬁcantly more clinical recurrences in the operated region
(REVAS: same site): 18% vs. 5%, p ¼ .002. In contrast, more different site recurrences were observed in the HLS
group: 50% vs. 31%, p ¼ .002. Duplex detected saphenofemoral reﬂuxes occurred more frequently after EVLA:
28% vs. 5%, p < .001. Both treatments improved disease severity and quality of life without any difference.
Conclusions: EVLA and HLS are comparably effective concerning overall REVAS, improvement of disease severity,
and quality of life. In terms of same site clinical recurrence and saphenofemoral reﬂuxes, HLS is superior to EVLA
5 years after treatment.
Clinical trial registration: ISRCTN18322872.
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Over the last 15 years endothermal techniques e laser and
radiofrequency ablation e have become well established
methods to treat saphenous vein incompetence challenging
open surgery with high ligation and stripping (HLS) as the
standard of care.1 Endovenous laser ablation (EVLA) repre-
sents the most commonly applied method within random-
ized controlled trials (RCT).2 A couple of these have
demonstrated equivalence of EVLA and HLS concerning
Table 1. Eligibility criteria.
Inclusion criteria Exclusion criteria
 Great saphenous vein
(GSV) incompetence
with saphenofemoral
and GSV reﬂux at least
down to the knee level
 Primary symptomatic
varicose veins, CEAP
clinical class  2 disease
 Age 18e65 years (at
randomization)
 Performance status
according to American
Society of
Anesthesiologists
(ASA) I-II
 Previous surgical
interventions in the
groin area, except
inguinal herniotomy
 Anterior or posterior
accessory saphenous
vein incompetence at
the same limb
 Small saphenous vein
incompetence requiring
treatment in the same
limb
 Acute deep venous
thrombosis or post-
thrombotic syndrome
 Known thrombophilia
associated with a high
risk of thromboembolism
 Arterial occlusive
disease > Fontaine IIA
and/or ankle brachial
index below 0.8
 Active malignancy
(diagnosed during the
past 5 years)
Results of a Randomized Clinical Trial (RELACS Study) 649safety, quality of life, and mid-term efﬁcacy.2 However,
strong evidence from long-term RCTs has not been provided
as only two groups published complete 5 year follow up
data from their trials comparing EVLA and surgery.3,4
Neither study was able to demonstrate signiﬁcant differ-
ences concerning clinical and duplex detectable recurrence,
venous severity scoring, and quality of life probably because
of small sample size. Consequentially, current systematic
reviews and meta-analyses have suggested a need for
further RCTs to reliably assess the long-term clinical efﬁcacy
of both treatments.2,5
The present RELACS trial (Randomized study comparing
Endovenous Laser Ablation with Crossectomy and Strip-
ping of the great saphenous vein; ISRCTN registry
18322872) was initiated in September 2004 and patient
enrolment ended in March 2007 with a cohort of 400
randomized patients. The short- and mid-term results
showed equivalent safety, quality of life, improvement of
disease severity, and freedom from clinical recurrence
throughout a 2 year follow up.6 Signiﬁcant differences
were detected concerning post-operative pain, phlebitic
reactions, pigmentation, and duplex recurrence favouring
open surgery, in contrast with convalescence, cosmetic
outcome, and haemodynamics (venous reﬁlling time),
which was superior in the EVLA group. The present and
second publication from the RELACS trial cover the 5 year
follow up results, focussing on long-term clinical and
duplex recurrence, venous severity scoring, quality of life,
and patient satisfaction. Poor compliance or
inability to understand
the study related
procedures
 Females pregnant or
breastfeedingMATERIALS AND METHODS
The study was conducted in two clinics, a university
dermatological department (Homburg) and a private vein
surgery centre (Bad Bertrich). The primary study objective
was clinical recurrence according to the classiﬁcation of
recurrent varicosities after surgery (REVAS).7 Secondary
objectives were duplex recurrence in the groin, treatment
related side effects, clinical and functional outcome (Hom-
burg Varicose Vein Severity Score: HVVSS),8 disease speciﬁc
quality of life (Chronic Venous Insufﬁciency Questionnaire:
CIVIQ-2),9 patients’ satisfaction, cosmetic outcome, and
recovery. Study objectives have been initially assessed for
up to 2 years after treatment and have already been pub-
lished.6 In the case of insigniﬁcant results concerning the
primary objective, the study protocol provided a further 5
year follow up examination. With the exception of short-
term complications (thromboembolic events, infection,
bruising, induration, and post-operative pain) and recovery,
all other primary and secondary study objectives have been
reassessed 5 years after treatment. The study protocol was
approved by the local ethics committee (Ärztekammer des
Saarlandes, identiﬁcation-no. 98/2004).
Study methodology has been reported in detail.6 In brief,
patients suffering from great saphenous vein (GSV) incom-
petence were screened according to deﬁned selection
criteria (Table 1). All participants eligible and willing to
attend gave their written informed consent prior torandomization. One limb per patient was allowed for
randomization. The random allocation sequence (two arms:
A ¼ EVLA, B¼HLS; 1:1 ratio; block size of 10, stratiﬁed ac-
cording to study site) was generated with the statistical
program package SPSS by the statistician. If a patient was
eligible for the trial, the responsible physician sent a
randomization FAX to the statistician and got the study
group assignment via FAX too. For treatment, the patients
of group A were assigned to Homburg and the group B
patients to Bad Bertrich, where the surgical procedures
were done exclusively by experienced surgeons (EVLA: KR;
HLS: NF, PG).
EVLA was performed with an 810 nm diode laser (MedArt
435, MedArt A/S, Hvidovre, Denmark) using bare ﬁbres and
Seldinger’s technique with 20 W power delivered in a
continuous pull back fashion. The intended energy dose
(energy ﬂuence equivalent [EFE]) was 20 J/cm2 vein surface
as recommended at the time of study protocol drafting.10
HLS consisted of transection of all groin tributaries to the
second branching level, ﬂush ligation of the saphenofemoral
650 K. Rass et al.junction with non-resorbable Ethibond 0e0, and neoreﬂux
protection with an invaginating Prolene 4e0 stump suture
serving as a barrier technique as previously described, fol-
lowed by stripping of the GSV to just below knee.11
Incompetent perforators and varicose veins were ligated
or removed by multiple stab avulsions in the same session
in both groups.
Peri- and post-operative conditions were identical in both
groups performing tumescent local anaesthesia and
included a single shot antibiotic prophylaxis, eccentric
compression bandage for the ﬁrst 24e48 hours, class II
thigh compression stockings for 4 weeks, and thrombosis
prophylaxis with tinzaparin for 6 days. Residual varicose
veins were solely treated with additional phlebectomies or
sclerotherapy at 3 month follow up.
Prior to treatment (day 1 or day 0) and at any follow up
visit (3, 12, 24, and 60 months after treatment), patients
were examined by standard clinical and Duplex procedures
using Siemens Sonoline Antaris, VF 10e5 (Siemens Medical
Solutions, Issaquah,WA) or Hewlett Packard Image Point HX
(Hewlett Packard, Wilmington, DE), and digital photo-
plethysmography (DPPG) (Vasoquant VQ 4000, ELCAT,
Wolfratshausen, Germany). In case of follow up delay, the
examination results were assigned to the preceding
scheduled visit; for life table analyses the exact time point
of presentation was used. A cross-over follow up was pro-
vided (patients were re-evaluated at both centres irre-
spective of their treatment).Analyzed
Figure 1. CONSORT chart showing the ﬂow of patients through the REL
protocol (PPP). 81.2% of the PPP were available for 5 year follow up. EVThe primary study objective e clinical recurrence e was
deﬁned as presence of any new visible or palpable vari-
cosity on the study leg noticed by the clinician. According to
REVAS, clinical recurrence was subclassiﬁed corresponding
to its origin (“Nature of source”).7 Recurrences having their
source at same site (NSs) were deﬁned as varicose veins
linked to the groin, to an incompetent GSV or perforator at
medial thigh level. As REVAS in its original version is
exclusively based on ﬁndings after surgical treatment, the
classiﬁcation was slightly modiﬁed to include the ﬁndings
after ELVA as well. Therefore subdivision NSs: “technical
failure” was replaced by “persisting or recurrent reﬂux” that
comprises reﬂuxing saphenofemoral junction (SFJ) with
recanalization of treated GSV (technical failure) as well as
reﬂuxing SFJ with anterior accessory saphenous vein (AASV)
reﬂux or reﬂux in groin tributaries.
All other clinical recurrences were speciﬁed as “Nature of
source, different site” (NDs).
A NSs recurrence requiring redo surgery was deﬁned as
follow up endpoint and those patients were excluded from
further follow up.
Secondary objectives were: (a) Duplex recurrence was
deﬁned as re-appearance of reﬂux in the groin >0.5 sec-
onds detected in vessels 2.0 mm connected with the
common femoral vein. In case of EVLA, reﬂux had to be
identiﬁed at least 2 cm distally from the saphenofemoral
junction; (b) clinical and functional outcome (HVVSS, Score
0e33); (c) disease speciﬁc quality of life (QoL; CIVIQ-2).Analyzed
ACS trial. Analyses were performed on the population treated per
LA ¼ endovenous laser ablation; HLS ¼ high ligation and stripping.
Table 2. Baseline patient demographics and clinical characteristics.
EVLA
(n ¼ 185a)
HLS
(n ¼ 161a)
p
Patient demographics
Median age, years
(range)
48 (22e67) 50 (18e66) .946
Gender (F/M), n 124/61 113/48 .563
Body mass index, kg/m2 26.2  4.1
(18.4e39.1)
26.3  4.9
(15.7e48.4)
.901
Limb characteristics
Side (R/L) 94/91 93/68 .234
CEAP, n (%)
C2 53 (29) 47 (29)
C3 95 (52) 76 (47)
C4 36 (20) 35 (22) .747
C5 1 (1) 2 (1)
C6 0 1 (1)
GSV diameter at SFJ, mm 8.7  2.8
(3.8e22.0)
8.7  2.2
(4.4e16.5)
.322
Body mass index, and GSV diameter are expressed as mean  1 SD
and range in parentheses.
EVLA ¼ endovenous laser treatment; GSV ¼ great saphenous vein;
HLS ¼ high ligation and stripping; SFJ ¼ saphenofemoral junction.
a Per protocol population.
Table 3. Clinical recurrences by REVAS classiﬁcation7 and
management.
EVLA
(n ¼ 152)
HLS
(n ¼ 129)
p
Overall REVAS, n (%) 69 (45) 70 (54) .152
Median follow up,
months (range)
60.4
(51.6e79.2)
60.7
(48.7e83.5)
.986
Topographical sites of REVAS
Groin 3 (4)a 4 (6) 1.000
Thigh 44 (64) 37 (52) .175
Popliteal fossa 8 (12) 10 (14) .802
Lower leg 46 (67) 45 (63) .725
Other 2 (3) 0 .241
Source of recurrence
Not detectable 34 (49) 50 (70) .015
SFJ 27 (39) 2 (3) <.001
Thigh perforator 3 (4) 10 (14) .078
SPJ 2 (3) 7 (10) .166
Lower leg perforator 6 (9) 8 (11) .780
Nature of source
Same site 27 (39) 7 (10) .002
Persisting or
recurrent reﬂuxb
27 0
Neovascularization 0 2
Uncertain 0 5
Different site 47 (68) 64 (91) .002
Persistent 1 0
New 46 64
Contribution from persistent incompetent GSV
GSV not detectable 59 (86) 68 (97)
Reﬂux above knee 10 1 .182
Reﬂux below knee 2 1
Management of REVAS
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course and assessed for the last 100 patients enrolled; (d)
overall satisfaction and cosmetic outcome (visual analogue
scale [VAS], range: 1e5); and (e) long-term side effects
(dysaesthesia, hyperpigmentation).
All scores used in these analyses (HVVSS, CIVIQ, VAS)
increase with disease severity or a worse outcome.Wait and see 34 (49) 47 (67) .040
Sclerotherapy 23 (33) 8 (11) .004
Phlebectomy 10 (14) 18 (26) .138
SFJ and/or GSV or AASV
redo treatment
6 (9) 0 .028
SSV surgery 1 (1) 3 (4) .620
Multiple selections were applicable for all topics resulting in
possible percentages >100%. All parameters are expressed as n
(%). EVLA ¼ endovenous laser treatment; GSV ¼ great
saphenous vein; HLS ¼ high ligation and stripping;
REVAS ¼ recurrent varicosities after surgery;
SFJ ¼ saphenofemoral junction; SPJ ¼ saphenopopliteal junction;
SSV ¼ small saphenous vein.
a Percentages refer to the group of patients with overall REVAS as
outlined in the ﬁrst line.
b Comprises reﬂuxing SFJ with recanalization of treated GSV
(technical failure) as well as reﬂuxing SFJ with AASV reﬂux or reﬂux
in groin tributaries.Statistical methods
A sample size of 200 patients per group was deﬁned for
enrolment to detect an 11% difference of REVAS as signif-
icant on a two sided 5% signiﬁcance level (a ¼ 0.05) with
90% statistical power (b ¼ 0.1) and assuming a dropout rate
of 10%.6
Qualitative variables were compared by chi-square test
between groups, quantitative variables by Mann-Whitney U
test. Intra-group differences of pre- and post-operative
continuous variables were compared by Wilcoxon ranked-
sum test. For the recurrence free rates, Kaplan-Meier ana-
lyses were performed and groups were compared with log-
rank test. A p value of <.05 was considered signiﬁcant. All
statistical analyses were performed with IBM SPSS Statistics
20 (IBM Corporation, Armonk, NY).
RESULTS
From a total of 421 patients invited to participate, 400
patients (i.e. 400 limbs) were randomized to EVLA (group A)
or HLS (group B). The numbers of patients treated and
examined at follow up schedule are shown in the Consort
diagram (Fig. 1). All study analyses were performed on the
sample treated per protocol (n ¼ 346).
Two hundred and eighty one patients (81%) were avail-
able for the 5 year analyses (EVLA 82%, HLS 80%, p ¼ .68)with median follow up times of 60.4 (EVLA) and 60.7
months (HLS), respectively (p ¼ .99). For the Kaplan-Meier
analyses all patients presenting at the 5 year follow up and
for those not attending the 5 year assessment, results from
the last follow up were used (there were 5 patients from
the EVLA group [3%] and 11 from the HLS group [7%] with
no follow up at all).
Baseline patient characteristics did not differ between
the groups (Table 2). Detailed EVLA parameters have been
652 K. Rass et al.reported earlier.6 EFE averaged 22.5  2.3 J/cm2 and linear
endovenous energy deposit 48.7  12.7 J/cm.Clinical recurrence according to REVAS
Overall clinical recurrence irrespective of extent and source
did not differ signiﬁcantly between the groups, and was
detected in 45% (EVLA) and 54% (HLS) 5 years after treat-
ment (p ¼ .152) (Table 3). In both groups the extent of new
varicose veins were similarly rated “slight” to “moderate”
with mean VAS1e5 of 1.49  0.63 (EVLT) and 1.53  0.68
(HLS) (p ¼ .82).
Recurrence in a narrower sense, represented as REVAS
“Nature of source: same site” e was found in 27 legs after
EVLA (18%) and in seven legs (5%) treated with HLS
(p ¼ .002).Figure 2. Kaplan-Meier curves showing recurrence-free rates. (A) Overa
Clinical recurrence with a nature of source at the operated site (REVAS
to an incompetent GSV or perforator at medial thigh level or as a resu
with AASV reﬂux or reﬂux in groin tributaries). (C) Clinical recurrence
“Nature of source: different site”, i.e. all other clinical recurrences not m
detected reﬂux at saphenofemoral junction. Differences between grou
ablation; HLS ¼ high ligation and stripping.REVAS “Nature of source: different site” resembling
clinical disease progression was detected more frequently in
the HLS group (50% vs. 31%, p ¼ .002). The Kaplan-Meier
analyses of clinical recurrence are shown in Fig. 2AeC.
The topographical appearance of recurrent and new
varicose veins, which occurred most often at the lower limb
level, showed no differences between the groups (Table 3).
In most patients the origin of recurrent varicosities was
deﬁned to be not detectable. This means that only side
branches without veriﬁable incompetent perforators were
present in those cases. A saphenofemoral source of recur-
rence, as assessed by Duplex ultrasound, was found in those
27 patients after laser ablation and in two patients after HLS
(p < .001).
Clinical recurrence was considered not to be medically
relevant in more patients after HLS providing a “wait-and-ll clinical recurrent varicosities after surgery (REVAS) (any site). (B)
“Nature of source: same site”, i.e. varicose veins linked to the groin,
lt of reﬂuxing SFJ with recanalization of ablated GSV, reﬂuxing SFJ
with a nature of source not located at the operated site (REVAS
atching the deﬁnition criteria for same site recurrence). (D) Duplex
ps were compared with log-rank test. EVLA ¼ endovenous laser
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patients (29%), sclerotherapy and/or phlebectomy was
recommended for treatment of REVAS (p ¼ .156). Six pa-
tients from the laser group developed an extensive recur-
rence from the saphenofemoral junction (SFJ) with a need
for reoperation by HLS (n ¼ 4) or Re-EVLA (n ¼ 2). As no
patient in the HLS group was affected by a relevant recur-
rence from the SFJ, the difference was signiﬁcant
(p ¼ .028). Table 3 summarizes the detailed REVAS data.
Duplex reﬂux at the saphenofemoral junction
Duplex detected reﬂux at the SFJ was signiﬁcantly more
common in the EVLA group at the 5 year follow up (42 legs,
28% vs. 6 legs, 5%, p < .001; Fig. 2D).
In 26 of the 42 legs demonstrating saphenofemoral reﬂux
after EVLA, GSV recanalization from the SFJ (62%) was
observed, and in 20 legs incompetent groin tributaries were
found, predominantly AASV reﬂux (48%). The mean reﬂux
length was 11.1  11.6 cm, ranging from 2.5 to 40 cm.
Twenty-seven of the 42 duplex detectable recurrences at
the SFJ were connected with clinical recurrence (64%) after
EVLA, six of whom were recommended for GSV redo
surgery.
The six legs with Duplex detectable SFJ reﬂux affected in
the HLS group revealed small vessels at the SFJ with di-
ameters between 2.2 and 3.7 mm, deﬁned as neo-
vascularization in four cases and veins developing from a
residual stump in two cases. Two cases of neo-
vascularization were connected with minor clinical recur-
rence without an indication for reoperation.
Homburg Varicose Vein Severity Score
HVVSS signiﬁcantly decreased from baseline to 3 months,
and further from 3 to 12 months, remained stable to 24Figure 3. Disease severity by HVVSS mean values from baseline to
5 years follow up. Score range 0e33. Differences from baseline to
3 months, from 3 months to 12 months, and from 2 years to 5
years after treatment were signiﬁcant (p < .001) without group
differences. Conﬁdence intervals have 95% coverage. EVLA:
endovenous laser ablation; HVVSS: Homburg Varicose Vein
Severity Score; HLS: high ligation and stripping.months, and worsened slightly but signiﬁcantly at 60
months after treatment without any difference between
the groups (Fig. 3). Overall HVVSS at 5 year follow up was
3.00  2.87 (EVLA) and 3.16  3.48 (HLS) (p ¼ .789). The
HVVSS subscores “objective clinical ﬁndings” (1.29  1.37
and 1.49  1.52, p ¼ .396) and “hemodynamic function”
(0.54  0.84 and 0.70  0.91, p ¼ .116) assessed by venous
reﬁlling time (DPPG) at the 5 year follow up were compa-
rable between the groups, whereas EVLA patients reported
signiﬁcantly more symptoms e pain, heaviness, swelling,
and itching (1.21  2.11 and 0.96  2.21, p ¼ .006).
CIVIQ-2
After a signiﬁcant improvement of QoL in the ﬁrst 3 and 12
post-operative months, CIVIQ-2 remained stable up to 60
months after treatment without signiﬁcant differences be-
tween the groups, either according to the overall score, or
to the different score items e pain, physical, psychological,
and social function e at any timepoint (Fig. 4, Table 4).
Patients’ satisfaction, cosmetic outcome, and long-term
side effects
Overall satisfaction with the treatment result was rated
1.28  0.51 (VAS1e5) after EVLA and 1.39  0.58 after HLS
at the 5 year follow up (p ¼ .078). The VAS scores for
cosmetic outcomes were 1.59  0.78 and 1.72  0.91
(p ¼ .301).
There were only a few cases of persistent dysaesthesia
(EVLA 3%, HLS 2%) or hyperpigmentation (EVLA 0%, HLS 1%)
5 years after treatment without signiﬁcant differences.
Finally, 99% (EVLA) and 97% (HLS) of the patients stated
that they would undergo each treatment again, if medically
necessary (p ¼ .509).Figure 4. Disease speciﬁc quality of life by CIVIQ-2 mean values
from baseline to 5 years’ follow up. Score range 0e100. Differ-
ences from baseline to 3 months after treatment for both groups
(p < .001), and from 3 months to 12 months for the HLS group
(p ¼ .01) were signiﬁcant without group differences. Conﬁdence
intervals have 95% coverage. CIVIQ-2: Chronic Venous Insufﬁciency
Questionnaire 2; EVLA: endovenous laser ablation; HLS: high liga-
tion and stripping.
Table 4. Health related quality of life (CIVIQ-2).9
EVLA HLS p
CIVIQ-2
(overall, 0e100)
n
(EVLT)
n
(HLS)
Baseline 47* 37* 28.6  18.5 29.4  16.2 .656
3 month follow up 43 37 12.8  13.8 18.0  15.7 .113
1 year follow up 40 32 10.5  14.2 11.1  13.5 .732
2 year follow up 41 33 10.8  12.7 9.5  11.3 .548
5 year follow up 32 27 11.8  14.8 11.0  11.9 .813
CIVIQ-2 (pain items, 0e20)
Baseline 7.0  4.8 7.4  4.4 .735
3 month follow up 3.0  3.3 4.6  4.0 .067
1 year follow up 2.5  3.4 3.0  3.5 .551
2 year follow up 2.6  3.4 2.7  3.4 .928
5 year follow up 2.5  3.3 3.1  3.3 .386
CIVIQ-2 (physical function, 0e20)
Baseline 4.7  4.4 5.4  4.1 .298
3 month follow up 2.4  3.4 3.4  3.5 .118
1 year follow up 1.6  2.6 2.2  2.5 .206
2 year follow up 1.8  3.2 1.6  2.1 .444
5 year follow up 1.8  3.3 2.1  2.5 .288
CIVIQ-2 (psychological function, 0e45)
Baseline 12.8  8.5 12.2  7.4 .857
3 month follow up 5.1  6.1 7.3  7.6 .175
1 year follow up 4.8  7.1 4.2  6.2 .902
2 year follow up 4.5  5.8 3.7  5.7 .339
5 year follow up 5.7  7.7 4.1  5.3 .619
CIVIQ-2 (social function, 0e15)
Baseline 4.1  3.3 4.3  2.6 .541
3 month follow up 2.3  2.5 2.7  2.7 .515
1 year follow up 1.7  2.4 1.7  2.4 .765
2 year follow up 1.8  2.5 1.5  1.9 .822
5 year follow up 1.9  2.3 2.0  2.4 .875
*CIVIQ was assessed in the last 100 patients enrolled; scores are expressed as mean  1 SD. CIVIQ-2 ¼ Chronic Venous Insufﬁciency
Questionnaire 2; EVLA ¼ endovenous laser treatment; HLS ¼ high ligation and stripping.
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The primary study objective of clinical recurrence, deﬁned
as any new varicose veins occurring in the treated limb
according to REVAS classiﬁcation,7 was not signiﬁcantly
different between the groups. This ﬁnding is in accordance
with results from other comparably designed RCTs
reporting 45e55% clinical relapse rates 5 years after EVLA
and after surgery.4,12 The clinical recurrences were rated as
moderate in the present study and did not remarkably
inﬂuence QoL. Using REVAS, recurrence can be focussed
on the treated area and it might be important to differ-
entiate between “real” recurrence originating from the
operated site and disease progression; the latter not being
an adequate parameter for treatment success evaluation.
From the medical and economic point of view, treatment
quality will be ﬁnally appraised by the necessity and fre-
quency of re-operations or re-interventions in the groin.
For this purpose, analyses were made of REVAS same site,
Duplex recurrence at the groin, and in consequence the
need for a treatment of groin recurrence. In all these as-
pects, HLS was found to be superior to EVLA 5 years after
treatment. A similar trend favouring HLS was found in the
RCT by Rasmussen et al. on a smaller sample size regarding
clinical recurrence with a detectable source of reﬂux (inthe GSV, AASV, and in the groin), which was detected in
16% of the EVLA group and in 9% of the HLS group.4 In the
present study, redo groin surgery was rated as necessary in
4% of all EVLA patients, but in none of the HLS patients.
Disselhoff et al. stated a comparable outcome in their 5
year analysis with four patients (7%) undergoing saphe-
nofemoral ligation after EVLA failure, and none in the
surgery group.3
Concerning Duplex detectable recurrence at the groin
level, a signiﬁcantly worse outcome was observed after
EVLA from 2 years after treatment onwards. It is interesting
that the Duplex recurrence rate after 2 years correlated
exactly with clinical recurrence from the saphenofemoral
junction (SFJ) after 5 years and could therefore be regarded
as a surrogate parameter for long-term clinical recurrence in
conformity with a previous study focussing on this topic.13
Therefore, carefully studying and reporting duplex recur-
rence at the SFJ not only after surgery, but also after
endovenous ablation, will provide important insights into
clinical recurrence development, especially in terms of
short- and mid-term RCTs.14
Flessenkämper et al. found signiﬁcantly different post-
procedure Duplex deﬁned SFJ reﬂux at 5 year follow up
(EVLT 40%, HLS 9%), similar to the present observations.12
Results of a Randomized Clinical Trial (RELACS Study) 655Rasmussen et al. reported a trend towards a better
outcome after HLS concerning detectable and reﬂuxing
GSVs 5 years after treatment (EVLA: 18%, HLS: 10%),
whereas Disselhoff et al. could not detect any signiﬁcant
difference between the groups in terms of saphenofemoral
reﬂux (EVLA: 22%, HLS: 28%).3,4 A second trial by Disselhoff
et al. with 5 years of follow up compared EVLA with (HL-
EVLA) and without saphenofemoral ligation. They demon-
strated comparable frequencies of groin varicose vein
recurrence: 21% in the EVLA group.15 In the latter trials,
duplex recurrences after HLS and after HL-EVLA were
classiﬁed as neovascularization in all cases (28% and 33%);
it is noteworthy that a barrier technique has not been re-
ported for the HLS and the HL-EVLA group, probably
contributing to this high recurrence rate compared with
the present ﬁndings. Barrier strategies as part of the sur-
gical technique have been implemented by several authors
over the last decade to contain neovascularization at the
SFJ, for example suture of the GSV stump, closure of the
cribriform fascia, silicone or PTFE patch saphenoplasty.
These strategies have been shown to prevent neo-
vascularization by 50e80%, and have therefore to be
considered mandatory within the scope of high liga-
tion.11,16e18 Besides neoreﬂux protection with a non-
resorbable stump suture working as a barrier in the pre-
sent study, the use of tumescent local anaesthesia can be
discussed as an additional protective factor warranting a
gentle and bloodless preparation and probably alleviating
surgical trauma and the risk of neovascularization in the
groin and along the strip track.
Different site clinical recurrence (REVAS “Nature of
source: different site”) was more common after HLS. This
phenomenon was observed in connection with an advan-
tageous venous reﬁlling time (DPPG) in the EVLA group
already at 2 year follow up, and it is speculated that the
hemodynamic situation after EVLA with a well preserved
antegrade ﬂow via groin tributaries might account for this.
Experimental data support this hypothesis suggesting that
an increase in venous ﬁlling pressure by vein ligation is
sufﬁcient to promote new veins becoming varicose distally
from the ligation by vein wall remodelling.19
With the exception of one RCT favouring HLS,20 all the
trials comparing EVLA with HLS irrespective of follow up
times showed no advantage for any one of the methods
concerning QoL and venous clinical severity scoring.3,4,21e26
As no differences were observed between the methods
concerning overall clinical recurrence in these trials, except
for one RCT favouring EVLA,23 this is not surprising.
There are some limitations of the present study. First,
each treatment was performed at a single centre. This could
have induced centre bias, for example in terms of different
intensities in performing the phlebectomies that in turn
could have inﬂuenced REVAS different site outcome. Sec-
ond, it would have been unethical to have completely
blinded the procedure to the patient by performing some
sort of sham operation in the groin on those assigned to
EVLA. Third, it could be that the laser energy was too low in
the present study. Laser energy deposits in other RCTsreporting 5 year data were in the range recommended later
on27,28 between 57 and 85 J/cm.3,4,12 The results of these
studies were all published after the present study was
initiated and all treatments had been completed. However,
as 18e40% saphenofemoral Duplex recurrences after 5
years were reported in these RCTs, comparable with the
outcome in the present study, underdosing of laser energy
seems unlikely.
In conclusion, endovascular techniques have been advo-
cated to offer beneﬁts over open surgical treatment in
terms of eliminating saphenous reﬂux, reducing side effects,
and improving patient discomfort and recovery.2 In current
meta-analyses and RCTs, advantages of endovenous radio-
frequency or laser ablation compared with open surgery are
conﬁned to post-operative pain in the ﬁrst week after
treatment and a quicker return to work.2,5,24,26 As the re-
sults of the present study demonstrate HLS as being supe-
rior with respect to long-term Duplex and same site clinical
recurrence, further studies including the next generation
endovascular techniques (radial laser, radiofrequency abla-
tion) and providing long-term data are urgently needed to
assess the real value of these techniques against open
surgery.
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